Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2575 in women with mild to moderate systemic lupus erythematosus
CTR20233944Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing lisaftoclax arm with placebo arm (2 arms). Primary endpoint: Safety and tolerability of APG-2575 in patients with systemic lupus erythematosus. Started Aug 2024; status: active.
02
Drugs
lisaftoclax
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20233944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233944.